CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
Myoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kang
Cancer Research and Treatment. 2017;49(2):350-357.   Published online 2016 July 19    DOI: https://doi.org/10.4143/crt.2016.067

Excel Download

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
Cancer Research and Treatment. 2017;49(2):350-357   Crossref logo
Link1 Link2

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
Yearbook of Oncology. 2008;2008:303-305   Crossref logo
Link1 Link2

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
Gastroenterology Research and Practice. 2014;2014:1-6   Crossref logo
Link1 Link2

4526 POSTER Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients after failure of imatinib mesylate treatment
European Journal of Cancer Supplements. 2007;5(4):306   Crossref logo
Link1 Link2

ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN: COST-UTILITY ANALYSIS
Value in Health. 2015;18(7):A464   Crossref logo
Link1 Link2

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
The Lancet. 2006;368(9544):1329-1338   Crossref logo
Link1 Link2

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
European Journal of Cancer. 2009;45(11):1959-1968   Crossref logo
Link1 Link2

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet. 2013;381(9863):295-302   Crossref logo
Link1 Link2

Imatinib/sunitinib
Reactions Weekly. 2016;1598(1):125-125   Crossref logo
Link1 Link2

7511 POSTER Safety and efficacy results of sunitinib from a worldwide treatment- use trial of gastrointestinal stromal tumour (GIST) patients (pts) with resistance or intolerance to prior imatinib therapy
European Journal of Cancer Supplements. 2007;5(4):405   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.